Glycinorm M 30/500mg OD Tablet (Gliclazide/Metformin )

Glycinorm-M 30/500mg OD Tablet: A Comprehensive Overview of Gliclazide/Metformin Combination Medication

Glycinorm-M 30/500mg OD Tablet is a pharmaceutical formulation that includes gliclazide and metformin, both of which are considered to be active components. People who have been diagnosed with type 2 diabetes mellitus typically receive a prescription for this tablet so that it can assist them in efficiently managing their blood sugar levels. This article intends to educate readers on Glycinorm-M’s composition, mode of action, therapeutic uses, dose, potential side effects, and precautions. This will be accomplished by offering a complete overview of the medication.

Glycinorm-M 30/500mg OD Tablet contains two key constituents:

Gliclazide: Gliclazide is an oral anti-diabetic drug classed as a sulfonylurea derivative. It accomplishes this by acting on the pancreatic beta cells to stimulate the secretion of insulin, which in turn helps bring down the amount of glucose in the blood. Gliclazide works by improving glucose utilisation in the periphery, which contributes further to the regulation of blood sugar levels.

Metformin: Metformin is an oral anti-diabetic medication that belongs to the biguanide class of drugs. It accomplishes this by decreasing the amount of glucose that is produced by the liver and by enhancing the sensitivity of peripheral tissues, such as muscle and adipose tissue, to insulin. Metformin enhances the way in which cells take up glucose, which ultimately results in a reduction in the amount of sugar in the blood.

Mechanism of Action

In order to provide superior glycemic control, the gliclazide and metformin action mechanisms that are included in the Glycinorm-M 30/500mg OD Tablet have been combined. Gliclazide works by encouraging the pancreas to secrete more insulin, primarily in reaction to meal-related spikes in blood glucose levels. This activity assists in lowering postprandial hyperglycemia, which ultimately contributes to an improvement in glycemic control.

Metformin, on the other hand, primarily targets the levels of glucose in the blood when the patient is fasting. Through its inhibition of gluconeogenesis and glycogenolysis, it brings to a reduction in the amount of glucose produced by the liver. Metformin improves insulin sensitivity in peripheral tissues, which in turn leads to an increase in glucose uptake by muscle cells and a reduction in insulin resistance.

In Glycinorm-M, the synergistic effects of gliclazide and metformin serve to moderate both fasting blood glucose levels as well as postprandial blood glucose levels, thereby offering comprehensive glycemic control.

Therapeutic Uses

The treatment of diabetes mellitus type 2 is the primary indication for the use of the Glycinorm-M 30/500 mg OD Tablet. When diet and exercise alone are not sufficient to control blood glucose levels in an adequate manner, a prescription for this medication may be made. Patients who have not achieved sufficient glycemic control with gliclazide or metformin monotherapy are good candidates for treatment with this drug since it is efficacious.

Related Product

Glycinorm 40 Tablet
Glycinorm 80 Tablet
Glycinorm 160 Tablet
Glycinorm OD 30mg Tablet
Glycinorm OD 60mg Tablet
Glycinorm Total 30 Tablet
Glycinorm Total 60 Tablet
Glycinorm M 30 OD Tablet
Glycinorm M 60 OD Tablet
Glycinorm M 40 Tablet
Glycinorm M 80 Tablet

Dosage and Administration

Glycinorm-M 30/500mg OD Tablet dosing should be determined by a healthcare practitioner based on individual patient factors, such as age, renal function, and overall health state. These considerations should be taken into consideration while making this determination. To lessen the likelihood of experiencing adverse effects on the digestive tract as a result of taking metformin, the tablet should normally be consumed orally once day in conjunction with a meal.

It is absolutely necessary to take the medication exactly as directed, including in terms of dosage and administration. It is possible to alter the desired treatment outcome by taking more or fewer tablets than what is prescribed.

Potential Side Effects

Glycinorm-M 30/500mg OD Tablet, like any other drug, has the potential to cause adverse effects in some patients. The following are the adverse reactions associated with this medicine that are claimed to occur most frequently:

1. Effects on the gastrointestinal tract could include feeling sick, throwing up, having diarrhoea, experiencing abdominal pain, and losing your appetite. These adverse effects are often modest and fleeting, and they go away as treatment is maintained.
2. Gliclazide, which is a type of sulfonylurea, has been linked to isolated cases of hypoglycemia, also known as low blood sugar levels. There is a possibility that you will have symptoms such as sweating, dizziness, trembling, confusion, and blurred vision. Consuming a glucose source with a rapid onset of action, such as a sweet drink or glucose pills, is an effective way to treat hypoglycemia as quickly as possible.
3. A potentially life-threatening condition known as lactic acidosis may be brought on by taking metformin, despite the fact that this side effect is rather infrequent. Muscle pain, fast breathing, lightheadedness, and discomfort in the abdomen region are all possible symptoms. Lactic acidosis requires rapid medical intervention.
4. It is extremely important to notify a healthcare practitioner as soon as possible about any severe or unexpected side effects. They are able to evaluate the circumstance and decide upon the appropriate next steps to take.

Precautions

It is imperative to take into consideration the following precautions before to beginning therapy with Glycinorm-M 30/500mg OD Tablet:

1. Allergic reactions: Individuals who are aware that they have a severe reaction to sulfonylureas, metformin, or any of the other components of the pill should not use it.
2. Metformin is mostly eliminated through the kidneys, making renal impairment a potential side effect. Adjusting the dosage or taking extra precautions is important when treating patients with renal impairment or severe renal dysfunction because of this.
3. Hepatic Impairment Patients who are taking Glycinorm-M may need to have their condition carefully monitored if they suffer from hepatitis. In the case of these individuals, a change to the dosage might be required.
4. The use of gliclazide is associated with an increased risk of hypoglycemia, which is especially concerning for elderly patients, patients who are underweight, and persons who have an irregular eating schedule. Maintaining glycemic control and avoiding episodes of hypoglycemia both need vigilant monitoring of blood glucose levels on a consistent basis.

Conclusion

Individuals who have type 2 diabetes mellitus have access to an effective treatment option in the shape of the Glycinorm-M 30/500mg OD Tablet, which is a combination drug consisting of gliclazide and metformin. Glycinorm-M helps regulate both fasting blood glucose levels as well as postprandial blood glucose levels, which ultimately leads to enhanced glycemic control. This is accomplished by combining the mechanisms of action of these two medicines. In order to achieve the best possible results from therapy, it is essential to take the dosage as directed, to report any adverse effects in a timely manner, and to observe any other necessary precautions. It is vital to consult a healthcare practitioner in order to assess whether or not Glycinorm-M is appropriate for particular patients and to resolve any concerns or questions relating to the medication’s application.